This article is more than 5 years old. Information may no longer be current.
New study will evaluate effect of workplace lifestyle intervention on CV risk factors
Click Here to Manage Email Alerts
Researchers have launched a 3-year study to determine whether a workplace-based lifestyle intervention, accompanied by imaging data, will lead to a reduction in the prevalence of CVD risk factors.
Valentin Fuster
The TANSNIP-PESA study will be led by Valentin Fuster, MD, PhD, director of Mount Sinai Heart and physician-in-chief of The Mount Sinai Hospital. The study will enroll adults aged 40 to 60 years at a corporation in Spain, according to a press release issued by Mount Sinai.
Employees will be divided into two groups based on high or low imaging-defined CV risk. Both groups will be randomly assigned to the comprehensive 3-year workplace lifestyle intervention or to standard occupational health care. Employees assigned the workplace-based lifestyle intervention will receive 12 personalized lifestyle counseling sessions during the 3-year period, an Ergotron sit-to-stand station and a Fitbit personal fitness monitor to self-monitor physical activity. Data will be collected at baseline, 1, 2 and 3 years, according to the release.
The primary outcome is FUSTER-BEWAT score, which consists of BP, physical activity, sedentary behavior, BMI, fruit and vegetable consumption, and smoking. Other outcomes studied will include changes in lifestyle, smoking, body weight, diet, vitality and quality of life, risk factor profiles, biomarkers and work-related outcomes such as productivity and absenteeism. The researchers will also review the cost-effectiveness of the intervention, compared with standard care, from both the societal and employer’s perspective, according to the release.
The researchers hypothesize that the level of compliance with the workplace-based lifestyle intervention will be higher in the group with high imaging-defined CV risk, compared to those with low imaging-defined CV risk.
“I fully expect that individual awareness of cardiovascular disease based on imaging, accompanied by a comprehensive 3-year work-based lifestyle intervention, will lead to a reduction in the prevalence of CV risk factors related to lifestyle,” Fuster stated in the release.
Disclosure: The TANSNIP Program is funded by a grant from AstraZeneca.